Nasdaq grts.

GRTS; Advanced Chart. Stock Screener · Earnings Calendar · Sectors · Nasdaq. Search Ticker. |. GRTS U.S.: Nasdaq. Gritstone bio Inc. Watchlist. Alert. NEW. Set ...Nov 17, 2023 · Gritstone Bio Inc (NASDAQ:GRTS) showed a performance of -33.50% in past 30-days. Number of shares sold short was 9.12 million shares which calculate 2.48 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.40 to the stock, which implies a rise of 86.83% to its current value. About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Find the latest dividend history for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Feb 10,2023 - GRTS STOCK PRICE DECREASE: Gritstone bio Inc on 02-10-2023 decreased stock price > 10% from $3.26 to $2.90. Dec 15,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-15-2022 increased stock price > 10% from $3.11 to $3.92. Dec 14,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-14-2022 increased stock price > 10% ...

Feb 10,2023 - GRTS STOCK PRICE DECREASE: Gritstone bio Inc on 02-10-2023 decreased stock price > 10% from $3.26 to $2.90. Dec 15,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-15-2022 increased stock price > 10% from $3.11 to $3.92. Dec 14,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-14 …

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Gritstone Bio Inc Gritstone Bio Inc GRTS Morningstar Rating Unlock Stock XNAS Rating as of Nov 27, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials...Gritstone bio ( NASDAQ: GRTS) uses its vaccine technology to promote an immune response against a patients cancer or to prevent or treat infectious disease. In late September, 2023, GRTS announced ...EMERYVILLE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next …WebEMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...The big shareholder groups in Gritstone Oncology, Inc. (NASDAQ:GRTS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone bio ( NASDAQ: GRTS) is developing a second-generation covid vaccine that is designed to work in two ways; first, it will generate a robust neutralizing antibodies response, and second ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Track Gritstone Bio Inc (GRTS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Sep 16, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...

EMERYVILLE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Follow. EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...

A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by ...

Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation May 26. Consensus revenue estimates increase to US$46.1m May 13. First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 07. Gritstone Oncology EPS beats by $0.41, beats on revenueApr 19, 2021 · The big shareholder groups in Gritstone Oncology, Inc. (NASDAQ:GRTS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have ... Today’s penny stock pick is the clinical-stage biotechnology company, Gritstone bio, Inc. (NASDAQ: GRTS). Gritstone bio, Inc. engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase …If you want to know who really controls Gritstone bio, Inc. (NASDAQ:GRTS), then you'll have to look at the makeup of its share registry. We can see that retail investors own the lion's share in the company with 43% ownership. ... NasdaqGS:GRTS Earnings and Revenue Growth October 6th 2023. Our data indicates that hedge funds own 16% of …Sep 16, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ... EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Find the latest news headlines from Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.First Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $153.2 million as of March 31, 2023, compared to $185.2 million as of December 31, 2022 ...9 มี.ค. 2566 ... (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today reported financial results ...

Gritstone bio ( NASDAQ: GRTS) is developing a second-generation covid vaccine that is designed to work in two ways; first, it will generate a robust neutralizing antibodies response, and second ...

EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced ...

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and ...Aug 1, 2023 · Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ... EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...The latest price target for Gritstone Bio ( NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023. The analyst firm set a price target for 7.00 expecting GRTS to rise to ...Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.GRTS Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 2.64. 861.WebGRTS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Gritstone bio, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.May 3, 2021 · Gritstone bio (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Instagram:https://instagram. spy costfcel newsbest mortgages in njbest real estate investment funds EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. mark mahaney stock picksbest mortgage lenders in new jersey EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ... list of blue chip stocks The big shareholder groups in Gritstone Oncology, Inc. (NASDAQ:GRTS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have ...The latest price target for . Gritstone Bio (NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023.The analyst firm set a price target for 7.00 expecting GRTS to rise to ...Gritstone bio ( NASDAQ: GRTS) is developing a second-generation covid vaccine that is designed to work in two ways; first, it will generate a robust neutralizing antibodies response, and second ...